Harbin Pharmaceutical Group Co Ltd
Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cere… Read more
Harbin Pharmaceutical Group Co Ltd (600664) - Net Assets
Latest net assets as of September 2025: CN¥6.41 Billion CNY
Based on the latest financial reports, Harbin Pharmaceutical Group Co Ltd (600664) has net assets worth CN¥6.41 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥14.08 Billion) and total liabilities (CN¥7.67 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥6.41 Billion |
| % of Total Assets | 45.51% |
| Annual Growth Rate | 7.78% |
| 5-Year Change | 52.67% |
| 10-Year Change | -18.63% |
| Growth Volatility | 17.23 |
Harbin Pharmaceutical Group Co Ltd - Net Assets Trend (1993–2024)
This chart illustrates how Harbin Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Harbin Pharmaceutical Group Co Ltd (1993–2024)
The table below shows the annual net assets of Harbin Pharmaceutical Group Co Ltd from 1993 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥6.09 Billion | +12.29% |
| 2023-12-31 | CN¥5.42 Billion | +9.53% |
| 2022-12-31 | CN¥4.95 Billion | +12.00% |
| 2021-12-31 | CN¥4.42 Billion | +10.83% |
| 2020-12-31 | CN¥3.99 Billion | -32.88% |
| 2019-12-31 | CN¥5.94 Billion | -5.38% |
| 2018-12-31 | CN¥6.28 Billion | -16.05% |
| 2017-12-31 | CN¥7.48 Billion | -9.84% |
| 2016-12-31 | CN¥8.30 Billion | +10.89% |
| 2015-12-31 | CN¥7.48 Billion | -14.68% |
| 2014-12-31 | CN¥8.77 Billion | -0.03% |
| 2013-12-31 | CN¥8.77 Billion | +1.40% |
| 2012-12-31 | CN¥8.65 Billion | +34.91% |
| 2011-12-31 | CN¥6.41 Billion | -2.02% |
| 2010-12-31 | CN¥6.55 Billion | +9.38% |
| 2009-12-31 | CN¥5.98 Billion | +3.38% |
| 2008-12-31 | CN¥5.79 Billion | +14.54% |
| 2007-12-31 | CN¥5.05 Billion | +1.81% |
| 2006-12-31 | CN¥4.96 Billion | +13.02% |
| 2005-12-31 | CN¥4.39 Billion | +12.45% |
| 2004-12-31 | CN¥3.91 Billion | +24.82% |
| 2003-12-31 | CN¥3.13 Billion | +8.73% |
| 2002-12-31 | CN¥2.88 Billion | +7.48% |
| 2001-12-31 | CN¥2.68 Billion | +64.76% |
| 2000-12-31 | CN¥1.63 Billion | +10.11% |
| 1999-12-31 | CN¥1.48 Billion | +16.10% |
| 1998-12-31 | CN¥1.27 Billion | +13.72% |
| 1997-12-31 | CN¥1.12 Billion | +41.71% |
| 1996-12-31 | CN¥788.98 Million | +17.39% |
| 1995-12-31 | CN¥672.12 Million | +5.26% |
| 1994-12-31 | CN¥638.52 Million | +7.11% |
| 1993-12-31 | CN¥596.14 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Harbin Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2454.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.63 Billion | 49.07% |
| Common Stock | CN¥2.52 Billion | 47.08% |
| Other Comprehensive Income | CN¥-68.99 Million | -1.29% |
| Other Components | CN¥274.91 Million | 5.14% |
| Total Equity | CN¥5.35 Billion | 100.00% |
Harbin Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Harbin Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Diös Fastigheter AB (publ)
F:D1F
|
$604.14 Million |
|
Changzhou Tronly New Electronic Materials Co Ltd
SHE:300429
|
$604.23 Million |
|
Pfeiffer Vacuum Technology AG
PINK:PFFVF
|
$604.24 Million |
|
Salfacorp
SN:SALFACORP
|
$604.31 Million |
|
Wetown Electric Group Co Ltd
SHG:688226
|
$603.87 Million |
|
NORVA24 GROUP AB (PUBL.)
F:WG0
|
$603.67 Million |
|
Pan Asian Microvent Tech (Jiangsu) Corp. A
SHG:688386
|
$603.55 Million |
|
Shenzhen Gas Corp Ltd
SHG:601139
|
$603.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Harbin Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,724,089,680 to 5,349,779,547, a change of 625,689,867 (13.2%).
- Net income of 628,846,606 contributed positively to equity growth.
- Dividend payments of 47,106,203 reduced retained earnings.
- Share repurchases of 3,982,526 reduced equity.
- Other comprehensive income increased equity by 825,794.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥628.85 Million | +11.75% |
| Dividends Paid | CN¥47.11 Million | -0.88% |
| Share Repurchases | CN¥3.98 Million | -0.07% |
| Other Comprehensive Income | CN¥825.79K | +0.02% |
| Other Changes | CN¥47.11 Million | +0.88% |
| Total Change | CN¥- | 13.24% |
Book Value vs Market Value Analysis
This analysis compares Harbin Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.62x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 14.64x to 1.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | CN¥0.23 | CN¥3.44 | x |
| 1994-12-31 | CN¥0.25 | CN¥3.44 | x |
| 1995-12-31 | CN¥0.27 | CN¥3.44 | x |
| 1996-12-31 | CN¥0.31 | CN¥3.44 | x |
| 1997-12-31 | CN¥0.44 | CN¥3.44 | x |
| 1998-12-31 | CN¥0.50 | CN¥3.44 | x |
| 1999-12-31 | CN¥0.70 | CN¥3.44 | x |
| 2000-12-31 | CN¥0.77 | CN¥3.44 | x |
| 2001-12-31 | CN¥1.26 | CN¥3.44 | x |
| 2002-12-31 | CN¥1.34 | CN¥3.44 | x |
| 2003-12-31 | CN¥1.45 | CN¥3.44 | x |
| 2004-12-31 | CN¥1.61 | CN¥3.44 | x |
| 2005-12-31 | CN¥1.84 | CN¥3.44 | x |
| 2006-12-31 | CN¥2.07 | CN¥3.44 | x |
| 2007-12-31 | CN¥2.40 | CN¥3.44 | x |
| 2008-12-31 | CN¥2.74 | CN¥3.44 | x |
| 2009-12-31 | CN¥2.84 | CN¥3.44 | x |
| 2010-12-31 | CN¥3.10 | CN¥3.44 | x |
| 2011-12-31 | CN¥2.54 | CN¥3.44 | x |
| 2012-12-31 | CN¥3.18 | CN¥3.44 | x |
| 2013-12-31 | CN¥3.35 | CN¥3.44 | x |
| 2014-12-31 | CN¥3.33 | CN¥3.44 | x |
| 2015-12-31 | CN¥2.80 | CN¥3.44 | x |
| 2016-12-31 | CN¥3.09 | CN¥3.44 | x |
| 2017-12-31 | CN¥2.77 | CN¥3.44 | x |
| 2018-12-31 | CN¥2.37 | CN¥3.44 | x |
| 2019-12-31 | CN¥1.96 | CN¥3.44 | x |
| 2020-12-31 | CN¥1.39 | CN¥3.44 | x |
| 2021-12-31 | CN¥1.53 | CN¥3.44 | x |
| 2022-12-31 | CN¥1.68 | CN¥3.44 | x |
| 2023-12-31 | CN¥1.91 | CN¥3.44 | x |
| 2024-12-31 | CN¥2.13 | CN¥3.44 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Harbin Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.75%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.89%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 2.73x
- Recent ROE (11.75%) is above the historical average (9.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 23.21% | 5.86% | 1.05x | 3.78x | CN¥78.23 Million |
| 1994 | 15.90% | 5.74% | 0.75x | 3.70x | CN¥37.45 Million |
| 1995 | 16.35% | 5.36% | 0.85x | 3.59x | CN¥42.40 Million |
| 1996 | 14.32% | 5.15% | 0.88x | 3.17x | CN¥33.94 Million |
| 1997 | 10.83% | 5.31% | 0.78x | 2.60x | CN¥9.23 Million |
| 1998 | 7.70% | 3.34% | 0.81x | 2.85x | CN¥-29.12 Million |
| 1999 | 9.42% | 3.09% | 1.02x | 3.00x | CN¥-8.49 Million |
| 2000 | 13.48% | 3.38% | 1.45x | 2.76x | CN¥56.20 Million |
| 2001 | 10.73% | 5.29% | 0.93x | 2.18x | CN¥19.26 Million |
| 2002 | 10.73% | 4.63% | 1.09x | 2.12x | CN¥20.46 Million |
| 2003 | 10.91% | 4.78% | 1.05x | 2.16x | CN¥27.51 Million |
| 2004 | 7.77% | 3.67% | 0.96x | 2.21x | CN¥-75.40 Million |
| 2005 | 11.84% | 5.37% | 0.98x | 2.24x | CN¥70.73 Million |
| 2006 | 10.78% | 5.04% | 0.99x | 2.17x | CN¥33.66 Million |
| 2007 | 11.73% | 7.14% | 0.88x | 1.87x | CN¥87.16 Million |
| 2008 | 14.90% | 8.89% | 1.00x | 1.67x | CN¥283.75 Million |
| 2009 | 15.60% | 8.74% | 1.07x | 1.67x | CN¥334.88 Million |
| 2010 | 17.36% | 9.02% | 1.07x | 1.81x | CN¥479.23 Million |
| 2011 | 9.08% | 4.31% | 1.15x | 1.83x | CN¥-58.89 Million |
| 2012 | 6.28% | 2.83% | 1.13x | 1.97x | CN¥-296.00 Million |
| 2013 | 2.07% | 0.93% | 1.10x | 2.02x | CN¥-646.32 Million |
| 2014 | 3.00% | 1.50% | 1.02x | 1.97x | CN¥-576.71 Million |
| 2015 | 8.23% | 3.66% | 1.15x | 1.95x | CN¥-125.15 Million |
| 2016 | 10.04% | 5.58% | 0.94x | 1.92x | CN¥2.86 Million |
| 2017 | 5.77% | 3.39% | 0.88x | 1.94x | CN¥-298.18 Million |
| 2018 | 5.90% | 3.20% | 0.91x | 2.03x | CN¥-240.40 Million |
| 2019 | 1.02% | 0.47% | 0.95x | 2.29x | CN¥-489.84 Million |
| 2020 | -30.97% | -9.99% | 0.91x | 3.40x | CN¥-1.43 Billion |
| 2021 | 9.65% | 2.90% | 1.00x | 3.34x | CN¥-13.64 Million |
| 2022 | 10.74% | 3.37% | 1.03x | 3.10x | CN¥32.04 Million |
| 2023 | 8.37% | 2.56% | 1.10x | 2.99x | CN¥-77.15 Million |
| 2024 | 11.75% | 3.89% | 1.11x | 2.73x | CN¥93.87 Million |
Industry Comparison
This section compares Harbin Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,143,363,278
- Average return on equity (ROE) among peers: -1.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Harbin Pharmaceutical Group Co Ltd (600664) | CN¥6.41 Billion | 23.21% | 1.20x | $603.93 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $578.17 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.22 Billion | 5.35% | 1.27x | $305.94 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $4.31 Billion | 24.13% | 0.24x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $541.80 Million | 8.52% | 0.09x | $1.85 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $1.42 Billion | 23.64% | 1.01x | $5.58 Billion |
| Hainan Haiyao Co Ltd (000566) | $208.64 Million | -29.76% | 3.24x | $665.35 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $259.16 Million | -10.12% | 1.64x | $311.31 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $4.12 Billion | 0.30% | 1.95x | $407.23 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $79.83 Million | 0.00% | 1.69x | $1.98 Billion |
| Renhe Pharmacy Co Ltd (000650) | $6.42 Billion | 8.95% | 0.19x | $777.45 Million |